OTX-2002
omega Theraputics
omega therapeutics presents new preclinical data supporting the first epigenomic controller, otx-2002, as a potential therapeutic approach in hepatocellular carcinoma at the esmo 2022 world congress on gastrointestinal cancer $omga 
Real-Time News, Market Data and Stock Quotes For Green Stocks @ https://t.co/70sW9CbveB